Objective: Kaliotoxin 2 (KTX2), a neurotoxin isolated from Androctonus australis hector scorpion venom, presents a high affinity with the voltage-gated potassium channels. The targets of KTX2 in the brain and its toxic effects on the cerebral cortex have been extensively studied; however, its deleterious systemic effects on other organ systems have not yet been investigated. Inflammatory response induced by KTX2 is supported by cytokine release which could provoke multiple organ dysfunction and diverse biological disorders in mammals. The possibility that inflammatory response and brain injuries induced by KTX2 may lead to functional disturbances, e.g. in the pancreas and the liver, were investigated. The contribution of IL-6 and TNF-α to the modulation of pathophysiological effects induced by KTX2 was also tested. Methods: NMRI mice were injected by the intracerebroventricular route with a sublethal dose of KTX2 or saline solution. Inflammatory response and oxidative stress were assessed in sera and tissue homogenates. Biomarkers of pancreatic and hepatic functions and the correlation with tissue damage in the brain, liver and pancreas were also analyzed. Results: The obtained results revealed that KTX2 injection induced an inflammatory process activation and imbalanced redox status. It also induced severe alterations in cerebral cortex, hepatic and pancreatic tissues associated with a significant increase in pancreatic and hepatic pathological biomarkers. Cytokine antagonists injected 30 min prior to KTX2 led to a significant reduction of all disturbances induced by KTX2. Conclusion: In addition to its significant toxicity on the central nervous system, KTX2 can also affect pancreatic and hepatic functions, probably by an indirect mechanism involving activation of the inflammatory response with release of IL-6 and TNF-α.

Keywords:
Kaliotoxin, Brain, Inflammatory response, Biological disorders
1.
Quintero-Hernandez V, Jimenez-Vargas JM, Gurrola GB, Valdivia HH, Possani LD: Scorpion venom components that affect ion-channels function. Toxicon 2013;76:328-342.
2.
De la Vega RCR, Vidal N, Possani LD: Scorpion peptides; in Kastin AJ (ed): Handbook of Biologically Active Peptides, ed 2. San Diego, Academic Press, 2013, pp 423-429.
3.
Laraba-Djebari F, Legros C, Crest M, Ceard B, Romi R, Mansuelle P, Jacquet G, van Rietschoten J, Gola M, Rochat H, et al: The kaliotoxin family enlarged. Purification, characterization, and precursor nucleotide sequence of KTX2 from Androctonus australis venom. J Biol Chem 1994;269:32835-32843.
4.
Bessone R, Martin-Eauclaire MF, Crest M, Mourre C: Heterogeneous competition of Kv1 channel toxins with kaliotoxin for binding in rat brain: autoradiographic analysis. Neurochem Int 2004;45:1039-1047.
5.
Martin-Eauclaire MF, Legros C, Bougis PE, Rochat H: Les toxines des venins de scorpion. Ann Inst Past 1999;10:207-222.
6.
Adi-Bessalem S, Hammoudi-Triki D, Laraba-Djebari F: Pathophysiological effects of Androctonus australis hector scorpion venom: tissue damages and inflammatory response. Exp Toxicol Pathol 2008;60:373-380.
7.
Sami-Merah S, Hammoudi-Triki D, Martin-Eauclaire MF, Laraba-Djebari F: Combination of two antibody fragments F(ab')(2)/Fab: an alternative for scorpion envenoming treatment. Int Immunopharmacol 2008;8:1386-1394.
8.
Martin MF, Rochat H: Large scale purification of toxins from the venom of the scorpion Androctonus australis hector. Toxicon 1986;24:1131-1139.
9.
Petricevich VL, Pena CF: The dynamics of cytokine d nitric oxide secretion in mice injected with Tityus serrulatus scorpion venom. Mediators Inflamm 2002;11:173-180.
10.
Laterra J, Keep RF, Lorris Betz A, Goldstein GW: Blood-brain-cerebrospinal fluid barriers; in Siegel GJ, Agranoff BW, Wayne Albers R, Fisher SK, Uhler MD (eds): Basic Neurochemistry. Molecular, Cellular and Medical Aspects, ed 6. Philadelphia, Lippincott Williams and Wilkins, 1999, pp 671-690.
11.
Ladjel-Mendil A, Martin-Eauclaire MF, Laraba-Djebari F: Neuropathophysiological effect and immuno-inflammatory response induced by kaliotoxin of Androctonus scorpion venom. Neuroimmunomodulation 2013;20:99-106.
12.
Petricevich VL: Balance between pro- and anti-inflammatory cytokines in mice treated with Centruroides noxius scorpion venom. Mediators Inflamm 2006;2006:54273.
13.
Petricevich VL: Scorpion venom and the inflammatory response. Mediators Inflamm 2010;2010:903295.
14.
Coelho FM, Pessini AC, Coelho AM, Pinho VS, Souza DG, Arantes EC, Teixeira MM, Teixeira AL: Platelet activating factor receptors drive CXC chemokine production, neutrophil influx and edema formation in the lungs of mice injected with Tityus serrulatus venom. Toxicon 2007;50:420-427.
15.
Van Oosterhout AJ, van Ark I, Hofman G, Van Der Linde HJ, Fattah D, Nijkamp FP: Role of interleukin-5 and substance P in development of airway hyperreactivity to histamine in guinea-pigs. Eur Respir J 1996;9:493-499.
16.
Moreno I, Pichardo S, Jos A, Gomez-Amores L, Mate A, Vazquez CM, Camean AM: Antioxidant enzyme activity and lipid peroxidation in liver and kidney of rats exposed to microcystin-LR administered intraperitoneally. Toxicon 2005;45:395-402.
17.
Ellman GL: Tissue sulfhydryl groups. Arch Biochem Biophys 1959;82:70-77.
18.
Winn-Deen ES, David H, Sigler G, Chavez R: Development of a direct assay for alpha-amylase. Clin Chem 1988;34:2005-2008.
19.
Nagy B: Muscle disease; in Kaplan LA, Pesce AJ (eds): Clinical Chemistry, Theory, Analysis and Correlation. St Louis, Mosby, 1984, p 514.
20.
Roeschlau P, Bernt E, Gruber W: Enzymatic determination of total cholesterol in serum. Z Klin Chem Klin Biochem 1974;12:226.
21.
Fossati P, Prencipe L: Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 1982;28:2077-2080.
22.
Kumar V, Abbas AK, Aster JC: Inflammation and repair; in Kumar V, Abbas AK, Aster JC (eds): Robbins Basic Pathology. Philadelphia, Elsevier Health Sciences, 2012, pp 29-74.
23.
Chen Q, Jin M, Yang F, Zhu J, Xiao Q, Zhang L: Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular formation and remodeling. Mediators Inflamm 2013;2013:928315.
24.
Magnan C, Ktorza AA: Production et sécrétion de l'insuline par la cellule β pancréatique. EMC Endocrinol 2005;2:241-264.
25.
Xu J, Wang P, Li Y, Li G, Kaczmarek LK, Wu Y, Koni PA, Flavell RA, Desir GV: The voltage-gated potassium channel kv1.3 regulates peripheral insulin sensitivity. Proc Natl Acad Sci U S A 2004;101:3112-3117.
26.
Robichon C, Girard J, Postic C: Can the hyperactivity of lipogenesis cause hepatic steatosis? A role for ChREBP (in French). Med Sci (Paris) 2008;24:841-846.
27.
Leroy J: Diabète sucré; in Scientifiques et Medicales Editions (ed): Encyclopédie vétérinaire, editions scientifiques et médicales. Paris, Elsevier SAS, 1991, pp 27-31.
28.
Ismail M: The scorpion envenoming syndrome. Toxicon 1995;33:825-858.
29.
Adi-Bessalem S, Mendil A, Hammoudi-Triki D, Laraba-Djebari F: Lung immunoreactivity and airway inflammation: their assessment after scorpion envenomation. Inflammation 2012;35:501-508.
30.
Kossakowska AE, Edwards DR, Prusinkiewicz C, Zhang MC, Guo D, Urbanski SJ, Grogan T, Marquez LA, Janowska-Wieczorek A: Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas. Blood 1999;94:2080-2089.
31.
Li H, Liang J, Castrillon DH, DePinho RA, Olson EN, Liu ZP: Foxo4 regulates tumor necrosis factor alpha-directed smooth muscle cell migration by activating matrix metalloproteinase 9 gene transcription. Mol Cell Biol 2007;27:2676-2686.
32.
Siasos G, Tousoulis D, Kioufis S, Oikonomou E, Siasou Z, Limperi M, Papavassiliou AG, Stefanadis C: Inflammatory mechanisms in atherosclerosis: the impact of matrix metalloproteinases. Curr Top Med Chem 2012;12:1132-1148.
33.
Kothari P, Pestana R, Mesraoua R, Elchaki R, Khan KM, Dannenberg AJ, Falcone DJ: IL-6-mediated induction of matrix metalloproteinase-9 is modulated by JAK-dependent IL-10 expression in macrophages. J Immunol 2014;192:349-357.
34.
Uemura S, Matsushita H, Li W, Glassford AJ, Asagami T, Lee KH, Harrison DG, Tsao PS: Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res 2001;88:1291-1298.
35.
Ho FM, Liu SH, Lin WW, Liau CS: Opposite effects of high glucose on MMP-2 and TIMP-2 in human endothelial cells. J Cell Biochem 2007;101:442-450.
36.
Matos IM, Souza DG, Seabra DG, Freire-Maia L, Teixeira MM: Effects of tachykinin NK1 or PAF receptor blockade on the lung injury induced by scorpion venom in rats. Eur J Pharmacol 1999;376:293-300.
37.
Adi-Bessalem S, Laraba-Djebari F: Lipid-derived inflammatory mediators: their role in pathogenesis of scorpion envenomation. Toxicon 2013;75:219.
38.
Mazzei de Davila CA, Davila DF, Donis JH, de Bellabarba GA, Villarreal V, Barboza JS: Sympathetic nervous system activation, antivenin administration and cardiovascular manifestations of scorpion envenomation. Toxicon 2002;40:1339-1346.
39.
Ghazal A, Ismail M, Abdel-Rahman AA, El-Asmar MF: Pharmacological studies of scorpion (Androctonus amoreuxi Aud. & Sav.) venom. Toxicon 1975;13:253-259.
40.
Ismail M, Abdullah ME, Morad AM, Ageel AM: Pharmacokinetics of 125i-labelled venom from the scorpion Androctonus amoreuxi, Aud. and Sav. Toxicon 1980;18:301-308.
41.
Borges A, Trejo E, Vargas AM, Cespedes G, Hernandez A, Alfonzo MJ: Pancreatic toxicity in mice elicited by Tityus zulianus and Tityus discrepans scorpion venoms. Invest Clin 2004;45:269-276.
42.
Ait-Lounis A, Laraba-Djebari F: TNF-α involvement in insulin resistance induced by experimental scorpion envenomation. PLoS Negl Trop Dis 2012;6:e1740.
43.
Senn JJ, Klover PJ, Nowak IA, Mooney RA: Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 2002;51:3391-3399.
44.
Rotter V, Nagaev I, Smith U: Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 2003;278:45777-45784.
45.
Lang CH, Dobrescu C, Bagby GJ: Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 1992;130:43-52.
46.
Fischer CP: Interleukin-6 in acute exercise and training: what is the biological relevance? Exerc Immunol Rev 2006;12:6-33.
47.
Nonogaki K, Fuller GM, Fuentes NL, Moser AH, Staprans I, Grunfeld C, Feingold KR: Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology 1995;136:2143-2149.
48.
Ryden M, Dicker A, van Harmelen V, Hauner H, Brunnberg M, Perbeck L, Lonnqvist F, Arner P: Mapping of early signaling events in tumor necrosis factor-alpha-mediated lipolysis in human fat cells. J Biol Chem 2002;277:1085-1091.
49.
Pedersen BK, Steensberg A, Fischer C, Keller C, Keller P, Plomgaard P, Febbraio M, Saltin B: Searching for the exercise factor: is IL-6 a candidate? J Muscle Res Cell Motil 2003;24:113-119.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.